Cambridge spin-out XO1, which is developing anticoagulants that could have a sizeable impact on preventing heart attacks and strokes, has received $11m from Index Ventures. The life science investor was the sole participant in the $11m round, made through Index’s $200m Life Sciences fund launched last year, and represents the company’s largest investment in a…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
